Fianlimab plus cemiplimab demonstrated modest clinical efficacy with an acceptable safety profile in patients with advanced malignancies across several tumor types mostly in treatment-naive patients. Further investigation is warranted.
Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies
Tae Min Kim·B Cho·Kyriakos P. Papadopoulos·O Hamid·Grace K. Dy·Ariel Birnbaum·John M. Kaczmar·Nehal Lakhani·D Rischin·Afshin Dowlati·Jyoti Malhotra·Jayakumar Mani·Fang Fang·Israel Lowy·Ahmed Khaled·Karl D. Lewis·Matthew G. Fury·Ray McDermott·Debashis Sarker·Xin‐Hua Zhu·Jean‐Francois Pouliot·Laura Brennan·Shuquan Chen·Mark Salvati·Glenn Kroog·Stephen K. Williamson